---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Antioxidant vitamin and mineral supplementation"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Antioxidant vitamin and mineral supplementation. Topics: Guideline recommendation for antioxidant supplementation in intermediate and advanced AMD, AREDS formulation and progression to advanced AMD, AREDS2 formulation: lutein and zeaxanthin in place of beta carotene, and Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/antioxidant-vitamin-and-mineral-supplementation"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Antioxidant vitamin and mineral supplementation

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Antioxidant Vitamin and Mineral Supplementation

<a id="topic-2.2.2.1.1-1"></a>

### Guideline recommendation for antioxidant supplementation in intermediate and advanced AMD

> “Randomized, controlled clinical trials support the use of antioxidant supplementation for slowing the progression to later stages of AMD”
> “Treatment with antioxidants and minerals as described previously in the original AREDS and AREDS2 trials should be considered for patients who have progressed to intermediate or advanced AMD in at least one eye.”
> “For participants with extensive intermediate (i.e., medium-sized) drusen in one or both eyes, one or more large drusen in at least one eye, non-subfoveal GA in one eye, or advanced AMD (i.e., subfoveal GA or CNV) in one eye, the rate of development of advanced AMD at 5 years was reduced by 25% in the participants using the combination treatment of antioxidant vitamins with zinc and copper.”
> “The results of the AREDS2 support the recommendation for substitution of beta-carotene with lutein (10 mg) and zeaxanthin (2 mg).”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

<a id="topic-2.2.2.1.1-2"></a>

### AREDS formulation and progression to advanced AMD

> “Participants were randomly assigned to receive daily oral tablets containing: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide; (3) antioxidants plus zinc; or (4) placebo.”
> “Average follow-up of the 3640 enrolled study participants, aged 55–80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52–0.98).”
> “The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54–0.99).”
> “Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.”

Source: [Age-Related Eye Disease Study Research Group (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1462955/)

<a id="topic-2.2.2.1.1-3"></a>

### AREDS2 formulation: lutein and zeaxanthin in place of beta carotene

> “Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD.”
> “Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).”
> “More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P = .04), mostly in former smokers.”
> “However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.”

Source: [Age-Related Eye Disease Study 2 Research Group (2013)](https://pubmed.ncbi.nlm.nih.gov/23644932/)

<a id="topic-2.2.2.1.1-4"></a>

### Supplementation and geographic atrophy progression toward the fovea: post hoc analysis of AREDS and AREDS2

> “Post hoc analysis of the Age-Related Eye Diseases Study (AREDS) and AREDS2, multi-center randomized placebo-controlled trials of oral micronutrient supplementation, each with 2×2 factorial design.”
> “392 eyes (318 participants) with GA in AREDS; 1210 eyes (891 participants) with GA in AREDS2.”
> “In AREDS eyes with non-central GA (n=208), proximity-based progression towards the central macula was significantly slower with randomization to antioxidants versus none, at 50.7 μm/year (95% CI 38.0–63.4 μm/year) versus 72.9 μm/year (95% CI 61.3–84.5 μm/year; p=0.012), respectively.”
> “In AREDS2 eyes with non-central GA, in participants assigned to AREDS antioxidants without β-carotene (n=325 eyes), proximity-based progression was significantly slower with randomization to lutein/zeaxanthin versus none, at 80.1 μm/year (95% CI 60.9–99.3 μm/year) versus 114.4 μm/year (95% CI 96.2–132.7 μm/year; p=0.011), respectively.”
> “In AREDS eyes with any GA (n=392), area-based progression was not significantly different with randomization to antioxidants versus none (p=0.63).”
> “Oral micronutrient supplementation slowed GA progression towards the central macula, likely by augmenting the natural phenomenon of foveal sparing.”

Source: [Keenan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11663139/)

Additional sources: [Evans and Lawrenson (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10498493/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
